Taylor A. Elfervig

Array ( [id] => 17532327 [patent_doc_number] => 20220110936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISEASES OR DISEASES CAUSED BY ABNORMALITY OF RNA BINDING PROTEIN AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/427404 [patent_app_country] => US [patent_app_date] => 2019-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443690 [patent_doc_number] => 20220064195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => SYNTHETIC I2 IMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS [patent_app_type] => utility [patent_app_number] => 17/413738 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413738 [rel_patent_id] =>[rel_patent_doc_number] =>)